E. Ohman J or Asset Management AB purchased a new position in shares of Twist Bioscience Corporation (NASDAQ:TWST – Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 8,287 shares of the company’s stock, valued at approximately $853,000.
Several other large investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its holdings in Twist Bioscience by 24.4% in the 2nd quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock valued at $97,000 after purchasing an additional 185 shares in the last quarter. Moody National Bank Trust Division purchased a new position in shares of Twist Bioscience during the 2nd quarter worth approximately $2,090,000. Perceptive Advisors LLC acquired a new stake in shares of Twist Bioscience in the 1st quarter valued at approximately $7,128,000. Western Wealth Management LLC acquired a new stake in shares of Twist Bioscience in the 1st quarter valued at approximately $31,000. Finally, Flax Pond Capital LLC purchased a new stake in shares of Twist Bioscience in the first quarter valued at approximately $76,000.
Twist Bioscience Price Performance
Shares of NASDAQ:TWST opened at $123.12 on Wednesday. The firm has a market capitalization of $7.72 billion, a price-to-earnings ratio of -55.46 and a beta of 2.14. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. The business’s 50 day simple moving average is $91.49 and its 200-day simple moving average is $65.64. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $125.66.
Analyst Ratings Changes
TWST has been the topic of a number of recent analyst reports. Evercore lowered Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price objective on the stock. in a report on Monday, July 6th. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a report on Monday, August 3rd. Barclays boosted their target price on shares of Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday, June 24th. Finally, Guggenheim increased their price target on shares of Twist Bioscience from $60.00 to $107.00 and gave the company a “buy” rating in a report on Monday, June 29th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $98.30.
View Our Latest Stock Report on TWST
Insider Transactions at Twist Bioscience
In related news, CEO Emily M. Leproust sold 18,880 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $95.00, for a total value of $1,793,600.00. Following the sale, the chief executive officer directly owned 824,039 shares in the company, valued at $78,283,705. The trade was a 2.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Paula Green sold 291 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $87.32, for a total transaction of $25,410.12. Following the completion of the sale, the senior vice president owned 120,414 shares in the company, valued at $10,514,550.48. This represents a 0.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 38,211 shares of company stock worth $3,525,891. Corporate insiders own 3.08% of the company’s stock.
About Twist Bioscience
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Read More
- Five stocks we like better than Twist Bioscience
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Corporation (NASDAQ:TWST – Free Report).
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
